AB3A Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Sarepta Therapeutics Inc

Watchlist Manager

Watchlist

Price: 15.3 EUR 4.22% Market Closed

Market Cap: €950.1m

S	Sarepta Therapeutics Inc XMUN:AB3A	US
V	Vinci SA XMUN:SQU	FR
D	Duke Energy Corp XBER:D2MN	US
M	Microsoft Corp DUS:MSF	US
P	PPG Industries Inc XMUN:PPQ	US
O	Oversea-Chinese Banking Corporation Ltd XMUN:OCBA	SG
	CompuGroup Medical SE & Co KgaA OTC:CMPUY	DE
C	Compass Group PLC F:XGR	UK
M	Metro AG XMUN:B4B	DE
K	Kardex Holding AG XMUN:KAX2	CH
A	Antofagasta PLC XMUN:FG1	UK
	Biffa PLC LSE:BIFF	UK

Profitability Summary

Sarepta Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

70%

Strong 3Y Average Gross Margin

82%

Declining Gross Margin

85% > 70%

Negative Operating Margin

-1%

Negative 3Y Average Operating Margin

-11%

Operating Margin is Increasing

-60% > -1%

Low Net Margin

Negative 3Y Average Net Margin

-19%

Net Margin is Increasing

-114% > 3%

Healthy Free Cash Flow Margin

Negative 3Y Average Free Cash Flow Margin

-30%

Free Cash Flow Margin is Increasing

-48% > 5%

Low ROE

Negative 3Y Average ROE

Negative 3Y Average ROIC

-11%

ROIC is Increasing

-58% > -2%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

70%

Strong 3Y Average Gross Margin

82%

Declining Gross Margin

85% > 70%

Negative Operating Margin

-1%

Negative 3Y Average Operating Margin

-11%

Operating Margin is Increasing

-60% > -1%